CompletedNCT02526030
Three-Year Comparison of Antipsychotics for First-Episode Psychosis
About this title
Read the official source — NCT02526030Medication studyAges 18–65SpainSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- SantanderSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: October 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 203
- Sponsor
- Fundación Marques de Valdecilla
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Spain
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT02526030
- Official title
Show the full official title
Phase IV Study of Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II): a 3-year Follow-up
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Santander
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Fundación Marques de Valdecilla.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole, Quetiapine and Ziprasidone.
Who was this study for?
Listed age limits: 18 years to 65 years.
